Genmab A/S (GNMSF)
509.50
0.00 (0.00%)
USD |
OTCM |
Nov 13, 16:00
Genmab EPS Diluted (Quarterly) : 5.480 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 5.480 |
| June 30, 2026 | 4.91 |
| March 31, 2026 | 0.83 |
| December 31, 2025 | 0.4609 |
| September 30, 2025 | 6.46 |
| June 30, 2025 | 5.463 |
| March 31, 2025 | 3.05 |
| December 31, 2024 | 8.529 |
| September 30, 2024 | 2.917 |
| June 30, 2024 | 3.132 |
| March 31, 2024 | 2.938 |
| December 31, 2023 | 1.395 |
| September 30, 2023 | 4.662 |
| June 30, 2023 | 2.963 |
| March 31, 2023 | 0.4598 |
| December 31, 2022 | 1.209 |
| September 30, 2022 | 5.301 |
| June 30, 2022 | 4.10 |
| March 31, 2022 | 1.063 |
| December 31, 2021 | 1.664 |
| September 30, 2021 | 2.135 |
| June 30, 2021 | 0.7523 |
| March 31, 2021 | 2.690 |
| December 31, 2020 | 1.402 |
| September 30, 2020 | 1.262 |
| Date | Value |
|---|---|
| June 30, 2020 | 7.582 |
| March 31, 2020 | 0.6031 |
| December 31, 2019 | 3.360 |
| September 30, 2019 | 1.234 |
| June 30, 2019 | 0.2032 |
| March 31, 2019 | 0.178 |
| December 31, 2018 | 2.055 |
| September 30, 2018 | 0.4509 |
| June 30, 2018 | 0.6731 |
| March 31, 2018 | 0.5281 |
| December 31, 2017 | 2.001 |
| September 30, 2017 | -0.0142 |
| June 30, 2017 | 0.7329 |
| March 31, 2017 | 0.0373 |
| December 31, 2016 | 1.973 |
| September 30, 2016 | 0.4589 |
| June 30, 2016 | 0.4128 |
| March 31, 2016 | -0.0281 |
| December 31, 2015 | 0.9463 |
| September 30, 2015 | 0.3426 |
| June 30, 2015 | 0.04 |
| March 31, 2015 | 0.5493 |
| December 31, 2014 | 0.1997 |
| September 30, 2014 | 0.4942 |
| June 30, 2014 | -0.0845 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Ascendis Pharma A/S | 1.239 |
| Zealand Pharma A/S | -0.1216 |
| Bavarian Nordic A/S | 0.305 |
| Evaxion AS | -0.4464 |
| ACADIA Pharmaceuticals, Inc. | 0.305 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 342.00M |
| Revenue (Quarterly) | 1.187B |
| Total Expenses (Quarterly) | 845.00M |
| Enterprise Value | 34.67B |
| Gross Profit Margin (Quarterly) | 90.31% |
| Profit Margin (Quarterly) | 28.81% |
| Earnings Yield | 2.29% |
| Operating Earnings Yield | 4.05% |
| Normalized Earnings Yield | 2.861 |